You just read:

Indivior Announces Positive Top-line Phase 3 Pivotal Study Results for RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder

News provided by

Indivior PLC

Aug 16, 2016, 19:01 ET